Bayerisches Zentrum für Krebsforschung (BZKF)
Research / Science organisation
Location:
Erlangen,
Germany (DE)
Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL (2022)
Blumenberg V, Busch G, Baumann S, Jitschin R, Winkelmann M, Hellwig K, Rejeski K, et al.
Conference contribution
Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis (2022)
Mahajan UM, Oehrle B, Sirtl S, Alnatsha A, Goni E, Regel I, Beyer G, et al.
Journal article
Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium (2022)
Lüke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spörl S, et al.
Journal article
Single-cell Transcriptome Analysis and clonal Kinetics in a Patient after CD19.CAR-T Cell Therapy (2022)
Lischer C, Eisenhauer N, Aigner M, Jacobs B, Schletter M, Gebhard C, Rehli M, et al.
Conference contribution
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition (2022)
Erlmeier F, Klümper N, Landgraf L, Strissel P, Strick R, Sikic D, Taubert H, et al.
Journal article